peptides for focus

updated

semax and selank are russian-academy prescription drugs with three decades of clinical use. dihexa is a wsu rodent compound whose c-met papers were retracted. those are not the same category.

the russian academy of sciences myasoedov institute developed semax (an acth 4-10 analog) and selank (a tuftsin analog) in the late 1980s. both are registered prescription drugs in russia with decades of clinical experience and bdnf or gabaergic mechanistic data, though no fda-grade phase-3 trial program. dihexa is the opposite profile: rodent work from joseph harding's lab at washington state university, whose 2012 and 2014 c-met/hepatocyte-growth-factor papers were retracted in 2025, zero human trials, and a theoretical cancer concern: oncology drugs target that pathway because it drives tumor growth.

russian prescription status, a US wakefulness indication, an acute task signal, and a rodent paper are different evidence lanes. none alone proves broad cognitive enhancement in rested people.

patient-neurology evidence, illness-related fatigue studies, preclinical antidepressant work, and an unresolved marketed identity do not become healthy-person cognitive-enhancement evidence.

the nootropic core.

compounds with documented cognitive, anxiolytic, or neuroimmune signal in the russian and eastern-european clinical record.

  • semax (tier B) · acth(4-10) heptapeptide analog, russian academy of sciences myasoedov institute, late 1980s. · the most concrete entry on this page. registered russian prescription drug for stroke and cognitive disorders, bdnf-upregulation mechanism, no fda-grade phase-3 program. the evidence base is real and geographically concentrated.
  • selank (tier B) · tuftsin analog from the same myasoedov lab as semax, anxiolytic profile. · gabaergic and neuroimmune signal, registered russian anxiolytic. paired with semax in community discussion but the mechanisms differ. closer to a non-sedating anxiolytic than a stimulant.
  • dsip (tier C) · delta sleep-inducing peptide, nonapeptide first isolated from rabbit brain dialysate in 1977. · not a focus drug. the trial record is on sleep and stress endpoints, much of it from the 1980s, and replication is thin. any focus claim is downstream of sleep, not a primary effect.
  • pinealon (tier C) · khavinson-program tripeptide (glu-asp-arg), st. petersburg institute of bioregulation and gerontology. · single-lab literature with neuroprotection claims and no independent western replication. interesting as a class artifact, not a cognitive-performance drug.

established pharmacology does not prove rested-person cognition.

approved uses, acute task signals, preclinical data, indirect mechanisms, and pathway-safety questions remain different evidence lanes.

  • nad+ (tier B) · not a peptide. dinucleotide cofactor central to mitochondrial energy metabolism, sold by iv infusion clinics. · kept on the page because focus searches surface it. biologically essential is not a cognitive-performance claim. there is no controlled outcome data supporting iv nad+ for focus, and the page calls that out rather than tiering it as peptide evidence.
  • epithalon (tier C) · russian longevity tetrapeptide (ala-glu-asp-gly) from the khavinson program. · the cognition claim is downstream of the longevity claim, which is itself based on narrow single-lab literature. weak as a focus reference.
  • dihexa (tier D) · angiotensin iv analog, joseph harding lab at washington state university. its 2012 and 2014 c-met papers were retracted in 2025. · the lab's 2013 rat memory paper also carries a notice of concern. if dihexa does act on c-met, that pathway is the target of approved oncology drugs because c-met activation drives tumor growth. zero human trials. the tier reflects the pathway risk, not the rodent novelty.
  • Methylene blue (tier A) · Methylene blue is a redox-active phenothiazinium drug. Its FDA approval treats acquired methemoglobinemia; cognition evidence is a small acute experiment, not a chronic nootropic program. · A 26-person single-exposure oral study found fMRI changes and a small memory-retrieval signal. It does not establish durable cognitive benefit, a chronic regimen, or long-term safety.
  • Modafinil (tier A) · Modafinil is an oral Schedule IV wake-promoting drug approved for excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift-work disorder. Those indications do not establish broad cognitive enhancement in rested healthy people. · Modafinil improves wakefulness in defined sleep disorders. A small severe sleep-deprivation experiment found task-specific effects, but sleep deprivation is not rested-user evidence and does not establish broad cognition, productivity, mood, or long-term safety claims.
  • pe-22-28 (tier C) · a seven amino acid peptide researched as an antidepressant, so far only in mice and in cells. three papers, one lab, zero humans, and the 23 hour duration printed on vendor pages was measured on a different molecule. · a seven amino acid peptide researched as an antidepressant. it blocks a potassium channel called TREK-1, and blocking that channel makes mice behave the way antidepressant drugs make them behave. the cell work runs a proper dose-response curve and the mouse results repeat, but every original paper comes from one CNRS lab, no human has ever received it, and how long it lasts in the body is unpublished.
  • cerebrolysin (tier D) · a liquid made from pig brain, dripped into a vein in hospital after a stroke or in dementia. thousands of randomised patients have been given it. every dose in every trial is measured in millilitres, because the ampoule holds a mixture and there is no single molecule to weigh, and the only published identity test is a fingerprint match against a reference sample. · doctors drip this pig-brain liquid into a vein to try to keep damaged brain cells alive after a stroke or a head injury, and to hold memory and thinking together in dementia. it does half of that. the scores taken in the first two weeks improve, and the three-month score that decides whether a stroke patient gets their independence back sits flat, with CASTA putting day-90 modified Rankin 0 to 2 at 199 of 529 against 208 of 541 on placebo. two cochrane reviews and three independent syntheses read the whole literature and rate every estimate low or very low.
  • adamax (tier D) · a marketed nootropic name whose exact chemical identity is not established by a cited primary characterisation. scoped PubMed and ClinicalTrials.gov searches found no exact-compound record. · Medsafe names Adamax as a marketed cognitive enhancer in an ACTH-analogue classification record, but that record does not establish its exact identity or effects. Exact PubMed and ClinicalTrials.gov searches found no Adamax-specific record, so efficacy, pharmacokinetics, and safety remain unknown.
  • bromantane (tier B) · a Russian antiasthenic CNS drug with older human studies in illness-related fatigue, incomplete modern replication, no traceable primary human half-life source, and in-competition WADA prohibition. · bromantane has a real Russian drug and human-study record for asthenia, but that record does not establish healthy cognitive enhancement, long-term safety, or the internet's preferred half-life number.
  • Noopept (omberacetam; GVS-111) (tier B) · omberacetam, a small-molecule cognitive drug sold as a registered 10 mg oral tablet in Russia. the cited human signal comes from one small patient comparison, not a healthy-user trial. · Noopept has a current Russian drug registration and a limited patient signal. It does not have placebo-controlled evidence of cognitive enhancement in healthy people, and sampled US supplements did not reliably define the exposure.

specific-question reference.

which nootropic peptide has the most concrete evidence?

semax. registered russian prescription for stroke and cognitive disorders since the 1990s, bdnf-upregulation mechanism, decades of myasoedov-lab and downstream clinical work. selank follows for anxiety and stress endpoints. neither has fda-grade phase-3 data, so confidence is not equivalent to an approved u.s. medication.

is dihexa a peptide?

borderline. it is a small-molecule angiotensin iv analog, hexamer-derived, not a standard amide-linked peptide drug. the reputation traces to harding's wsu rodent papers: the 2013 rat memory paper carries a notice of concern and the 2012 and 2014 c-met papers were retracted in 2025. zero human cognitive trials.

does dsip improve focus?

not in the published record. the trial signal is on sleep and stress, mostly from the 1980s. any focus claim is a downstream sleep-quality hypothesis, not a primary cognitive effect.

what does the page avoid?

stack advice, psychiatric self-treatment framing, or claims that a peptide can replace sleep, diagnosis, therapy, or prescribed medication.

do any peptides improve memory?

no reliable evidence in healthy people; weak evidence in patients. semax's developers wrote in 1997 that it improves memory in healthy men under extreme conditions, giving no sample size or effect size in the abstract (Ashmarin, Zh Vyssh Nerv Deiat Im I P Pavlova 1997); two later placebo-controlled studies of 24 and 52 healthy people measured resting brain activity within 20 minutes of semax or selank, not memory (Lebedeva, Bull Exp Biol Med 2018; Panikratova, Dokl Biol Sci 2020). a Cochrane review of cerebrolysin's 6 vascular-dementia trials, 597 people, rated its cognition benefit very low quality (Cui, Cochrane Database Syst Rev 2019). dihexa's memory data are rodent: its 2013 rat paper carries a notice of concern (McCoy, J Pharmacol Exp Ther 2013), its lab's 2012 and 2014 c-met papers were retracted (retraction notices, J Pharmacol Exp Ther 2025), and the c-met cancer concern is untested in people.

what the safety literature reports.

what safety gap matters most?

lack of modern, well-powered human trials for most of these compounds. absence of dramatic community harm reports is not a formal safety dataset.

why is dihexa treated cautiously?

the c-met/hepatocyte-growth-factor pathway is the same target as approved tumor-suppressing oncology drugs (capmatinib, tepotinib). the 2014 paper tying dihexa's rodent cognition effects to that pathway was retracted in 2025, so the risk is theoretical. agonizing it chronically in humans without trial data would be a different proposition.

why does regulation matter?

russian prescription use, u.s. research-chemical availability, and fda approval are different categories. semax has the first, has the second in the u.s. peptide market, and does not have the third. they should not be conflated.

claim checks

related comparisons

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.